Edward M. Sellers

Edward M. Sellers's AcademicInfluence.com Rankings

Edward M. Sellers

Computer Science

#3053

World Rank

#3202

Historical Rank

Machine Learning

#283

World Rank

#286

Historical Rank

Artificial Intelligence

#458

World Rank

#466

Historical Rank

Database

#580

World Rank

#608

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Edward M. Sellers's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Edward M. Sellers Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Edward M. Sellers's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A method for estimating the probability of adverse drug reactions (1981) (9974)
Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). (1989) (1572)
Drug disposition in old age. (1982) (577)
A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. (1997) (469)
Nicotine metabolism defect reduces smoking (1998) (434)
Binding of Drugs to Serum Albumin (1976) (417)
Alcohol intoxication and withdrawal. (1976) (401)
Cortical γ-Aminobutyric Acid Levels Across the Menstrual Cycle in Healthy Women and Those With Premenstrual Dysphoric Disorder: A Proton Magnetic Resonance Spectroscopy Study (2002) (327)
Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. (2004) (325)
5-HT and alcohol abuse. (1992) (309)
Measurement issues in postpartum depression part 1: Anxiety as a feature of postpartum depression (2003) (304)
Drug Interactions with Coumarin Anticoagulants (1971) (286)
Withdrawal reaction after long-term therapeutic use of benzodiazepines. (1986) (277)
Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence (2005) (262)
Inhibition by fluoxetine of cytochrome P450 2D6 activity (1993) (259)
Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. (2000) (246)
The serotonin uptake inhibitor citalopram attenuates ethanol intake (1987) (237)
Inhibition of cytochromes P450 by antifungal imidazole derivatives. (2002) (232)
Venlafaxine oxidation in vitro is catalysed by CYP2D6. (1996) (223)
Zimelidine‐induced variations in alcohol intake by nondepressed heavy drinkers (1984) (218)
Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers (1990) (215)
Development of optimal treatment tactics for alcohol withdrawal. I. Assessment and effectiveness of supportive care. (1981) (213)
Diazepam loading: Simplified treatment of alcohol withdrawal (1983) (203)
Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. (1994) (194)
Interactions of amphetamine analogs with human liver CYP2D6. (1997) (190)
CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone (1993) (177)
Drug therapy. Binding of drugs to serum albumin (second of two parts). (1976) (165)
Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking (2000) (165)
Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. (2001) (161)
Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. (2002) (155)
In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution. (1983) (150)
An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. (2002) (140)
Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. (1997) (140)
Challenges in the Development of Prescription Opioid Abuse-deterrent Formulations (2007) (140)
Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. (2001) (140)
Human dopamine transporter gene: coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations (2000) (138)
Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence. (2001) (134)
Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N‐acetyltransferase‐2, and xanthine oxidase activities with the “Cooperstown 5+1 cocktail” (2003) (133)
Drug interactions with coumarin anticoagulants. 2. (1971) (131)
Importance of Protein Binding for the Interpretation of Serum or Plasma Drug Concentrations (1982) (130)
Genetic Variation in CYP2A6-Mediated Nicotine Metabolism Alters Smoking Behavior (2002) (129)
Modulation of ethanol intake by serotonin uptake inhibitors. (1986) (127)
CYP2A6 genetic variation and potential consequences. (2002) (124)
Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study (2006) (123)
Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. (1995) (120)
Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166) (1999) (119)
Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids (1970) (112)
Drug Kinetics and Alcohol Ingestion (1978) (111)
Alcohol withdrawal severity is decreased by symptom-orientated adjusted bolus therapy in the ICU (2003) (110)
NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. (1998) (107)
Interaction of chloral hydrate and ethanol in man: I. Metabolism (1972) (106)
Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. (1993) (105)
Methadone binding to orosomucoid (α1‐acid glycoprotein): Determinant of free fraction in plasma (1981) (105)
KINETICS AND CLINICAL IMPORTANCE OF DISPLACEMENT OF WARFARIN FROM ALBUMIN BY ACIDIC DRUGS * (1971) (104)
Novel Pharmacological Interventions for Alcoholism (1992) (101)
A Clinical Scale to Assess Benzodiazepine Withdrawal (1989) (100)
Drug therapy: Drugs to decrease alcohol consumption. (1981) (100)
Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor Metabolizers (2004) (99)
Protein binding and vascular activity of diazoxide. (1969) (99)
Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. (1998) (97)
Clinical Pharmacokinetics of Non-Opiate Abused Drugs (1989) (97)
Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate. (1970) (96)
Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. (1982) (94)
Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial (2018) (93)
Gender differences in tobacco smoking: higher relative exposure to smoke than nicotine in women. (2002) (93)
Characteristics of dependent and nondependent regular users of codeine. (1999) (93)
Age‐ and Gender‐Related Differences in Diazepam Pharmacokinetics (1979) (93)
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. (2001) (91)
3α-reduced neuroactive steroids and their precursors during pregnancy and the postpartum period (2005) (91)
Withdrawal reaction after long-term therapeutic use of benzodiazepines (1987) (91)
Treatment of acetaminophen poisoning. (1981) (91)
From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists. (2013) (90)
In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. (1983) (89)
Effect of drugs influencing 5-HT function on ethanol drinking and feeding behaviour in rats: Studies using a drinkometer system (1992) (89)
Nicotine physical dependence and tolerance in the mouse following chronic oral administration (2005) (88)
Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent (2008) (87)
Differential effects of viqualine on alcohol intake and other consummatory behaviors (1989) (87)
Antagonist-precipitated opioid withdrawal in rats: Evidence for dissociations between physical and motivational signs (1994) (86)
Regional and cellular distribution of CYP2D subfamily members in rat brain (2000) (86)
Inter‐ and intrasubject variation in diazepam free fraction (1979) (86)
Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. (1999) (85)
Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers. (1989) (84)
Nonpharmacologic intervention in acute alcohol withdrawal (1983) (84)
Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. (2007) (84)
Patterns of benzodiazepine abuse and dependence. (1986) (83)
Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver. (2001) (82)
A randomized, double‐blind, placebo‐controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use (2011) (80)
The NMDA antagonist dizocilpine (MK801) attenuates motivational as well as somatic aspects of naloxone precipitated opioid withdrawal. (1992) (80)
Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management. (1988) (80)
Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo (1997) (79)
Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. (1997) (79)
Pharmacokinetic Determinants of Drug Abuse and Dependence (1986) (79)
Comparative efficacy of propranolol and chlordiazepoxide in alcohol withdrawal. (1977) (77)
CYP2A6 Genotype, Phenotype, and the Use of Nicotine Metabolites as Biomarkers during Ad libitum Smoking (2006) (75)
Median and dorsal raphe injections of the 5-HT1A agonist, 8-OH-DPAT, and the GABAA agonist, muscimol, increase voluntary ethanol intake in wistar rats (1994) (75)
Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. (2001) (74)
An open-label, multi-dose efficacy and safety study of intramuscular tetrodotoxin in patients with severe cancer-related pain. (2007) (73)
Decreasing smoking behaviour and risk through CYP2A6 inhibition. (2003) (72)
Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. (2002) (71)
Plasma Protein Binding of Diazepam and Tolbutamide in Chronic Alcoholics (1976) (71)
The ambiguity of adverse drug reactions (1977) (69)
Objective determination of benzodiazepine use and abuse in alcoholics. (1983) (67)
Pharmacogenetics and ethnoracial differences in smoking. (1998) (66)
Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. (2003) (66)
Morphine place conditioning is differentially affected by CCKA and CCKB receptor antagonists (1992) (65)
Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat. (1995) (64)
Multiple drug use and psychiatric comorbidity in patients admitted to the hospital with severe benzodiazepine dependence. (1996) (64)
Plasma protein displacement interactions are rarely of clinical significance. (1979) (64)
Propranolol Effect on Tremor in Alcoholic Withdrawal (1975) (63)
CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. (2003) (63)
The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting (2016) (63)
Benzodiazepines and Ethanol: Assessment of the Effects and Consequences of Psychotropic Drug Interactions (1982) (63)
The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. (2003) (63)
Clinical Pharmacokinetics of Chlordiazepoxide (1975) (62)
Alprazolam and benzodiazepine dependence. (1993) (62)
Drug therapy: drug disposition in old age. (1982) (61)
Research design strategies to evaluate the impact of formulations on abuse liability. (2006) (60)
Diazepam tapering in detoxification for high‐dose benzodiazepine abuse (1984) (59)
Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users (2013) (59)
Chlordiazepoxide and oxazepam disposition in cirrhosis (1979) (59)
Influence of age and previous use of diazepam dosage required for endoscopy. (1978) (58)
Evaluation of the Abuse Potential of Lorcaserin, a Serotonin 2C (5‐HT2C) Receptor Agonist, in Recreational Polydrug Users (2011) (58)
Subjective Effects and Safety of Whole and Tampered Morphine Sulfate and Naltrexone Hydrochloride (ALO-01) Extended-Release Capsules versus Morphine Solution and Placebo in Experienced Non-Dependent Opioid Users (2009) (57)
Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans (1994) (56)
Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. (2003) (54)
Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. (2000) (54)
CYP2D6 inhibition in patients treated with sertraline. (1997) (54)
Clinical aspects of chronic use of alprazolam and lorazepam. (1995) (54)
Effects of 5-HT3, D1 and D2 Receptor Antagonists on Ethanol- and Cocaine-Induced Locomotion (1997) (54)
Do Formulation Differences Alter Abuse Liability of Methylphenidate?: A Placebo-Controlled, Randomized, Double-Blind, Crossover Study in Recreational Drug Users (2007) (53)
Intravenous diazepam and oral ethanol interaction (1980) (53)
Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. (2001) (52)
Effect of a Triphasic Oral Contraceptive on Drug‐Metabolizing Enzyme Activity as Measured by the Validated Cooperstown 5+1 Cocktail (2005) (51)
A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo (2009) (49)
Characterization of DSM-III-R criteria for uncomplicated alcohol withdrawal provides an empirical basis for DSM-IV. (1991) (49)
Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. (1995) (49)
The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. (2002) (49)
Long-term codeine use is associated with depressive symptoms. (1999) (49)
Diurnal variations in plasma diazepam concentrations associated with reciprocal changes in free fraction. (1980) (49)
Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations (2012) (48)
Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. (2005) (47)
Rat Hepatic CYP2E1 Is Induced by Very Low Nicotine Doses: An Investigation of Induction, Time Course, Dose Response, and Mechanism (2003) (47)
Update on tamper-resistant drug formulations. (2013) (47)
Effect of the 5-HT3 antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure (1995) (47)
Quantitation of phencyclidine in biological fluids and application to human overdose. (1976) (47)
Evaluation of the Abuse Potential of Extended Release Hydromorphone Versus Immediate Release Hydromorphone (2010) (47)
Interaction of chloral hydrate and ethanol in man: II. Hemodynamics and performance (1972) (47)
Intravenous phenobarbital therapy in barbiturate and other hypnosedative withdrawal reactions: A kinetic approach (1979) (47)
Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4. (2001) (46)
Mimicking Gene Defects to Treat Drug Dependence (2000) (46)
Assessing Abuse Liability During Drug Development: Changing Standards and Expectations (2008) (46)
Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome. (1986) (45)
Propranolol and chlordiazepoxide effects on cardiac arrhythmias during alcohol withdrawal. (1980) (44)
Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. (2001) (44)
Behavioral effects of the 5-hydroxytryptamine3 receptor agonists 1-phenylbiguanide and m-chlorophenylbiguanide in rats. (1993) (44)
A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. (1999) (44)
Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. (1998) (43)
Use of Remifentanil in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ-Receptor Antagonist (2015) (43)
Subjective and Objective Effects of the Novel Triple Reuptake Inhibitor Tesofensine in Recreational Stimulant Users (2010) (42)
Interaction of disulfiram with benzodiazepines (1978) (42)
Management of the Alcohol withdrawal Syndrome (1991) (41)
Assessment of Pharmacokinetics and Pharmacodynamic Effects Related to Abuse Potential of a Unique Oral Osmotic‐Controlled Extended‐Release Methylphenidate Formulation in Humans (2007) (41)
Do serotonin uptake inhibitors decrease smoking? Observations in a group of heavy drinkers. (1987) (41)
Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies (1998) (41)
Ethanol effects on drug release from Verapamil Meltrex, an innovative melt extruded formulation. (2009) (40)
INTERACTION OF WARFARIN STEREOISOMERS WITH HUMAN ALBUMIN (1975) (40)
Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. (1997) (39)
Effect of the 5-HT3 receptor antagonists, MDL72222 and ondansetron on morphine place conditioning (2005) (39)
Binding of drugs to serum albumin (first of two parts). (1976) (39)
Attractiveness of reformulated OxyContin® tablets: assessing comparative preferences and tampering potential (2013) (39)
Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers (2010) (38)
Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma. (1981) (38)
Human Abuse Liability of the Smoking Cessation Drug Varenicline in Smokers and Nonsmokers (2008) (38)
New CYP2A6 gene deletion and conversion variants in a population of Black African descent. (2010) (37)
Is there acute tolerance to alcohol at steady state? (1985) (37)
Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. (2007) (36)
Inhibition of Nicotine Metabolism by Methoxysalen: Pharmacokinetic and Pharmacological Studies in Mice (2007) (36)
Lack of interaction of buprenorphine with flunitrazepam metabolism. (2000) (36)
The disulfiram and calcium carbimide acetaldehyde-mediated ethanol reactions. (1981) (36)
Opportunities for treatment of psychoactive substance use disorders with serotonergic medications. (1991) (35)
Amitriptyline and ethanol: Pharmacokinetic and pharmacodynamic interaction (2004) (35)
Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users (2015) (35)
Medication discontinuation in panic disorder. (1992) (35)
Difficulties in assessing adverse drug reactions in clinical trials (1982) (35)
Acute and chronic drug abuse emergencies in Metropolitan Toronto. (1981) (35)
Cytochrome P450 2D6 and treatment of codeine dependence. (2000) (34)
Pharmacologic aspects of benzodiazepine tolerance and dependence. (1991) (34)
Benzodiazepine-associated emergencies in Toronto. (1980) (34)
Effect of alcohol on cardiovascular reflexes. (1977) (34)
A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation. (1998) (34)
INFLUENCE OF INTRAVENOUS INJECTION RATE ON PROTEIN BINDING AND VASCULAR ACTIVITY OF DIAZOXIDE * (1973) (34)
Effect of short‐ and long‐term alcohol use on phenytoin kinetics in chronic alcoholics (1981) (34)
Comparative drug adsorption by activated charcoal. (1977) (34)
Simultaneous gas chromatographic determination of methamphetamine, amphetamine and their p-hydroxylated metabolites in plasma and urine. (1997) (34)
Evaluation of zopiclone physical dependence liability in normal volunteers. (1983) (33)
Triazolam and ethanol interaction: Kinetic and dynamic consequences (1985) (33)
Barbiturate and hypnosedative withdrawal by a multiple oral phenobarbital loading dose technique (1981) (33)
Measurement issues in postpartum depression part 2: Assessment of somatic symptoms using the Hamilton Rating Scale for Depression (2003) (32)
The CCKA receptor antagonist devazepide does not modify opioid self-administration or drug discrimination: comparison with the dopamine antagonist haloperidol (1994) (32)
Comparative Metabolism of Chloral Hydrate and Triclofos (1978) (31)
The quantitative assessment of physical dependence on opiates. (1978) (31)
Comparative abuse liability of intravenously administered remifentanil and fentanyl. (2000) (31)
Ezetimibe does not affect the pharmacokinetics of oral contraceptives (2001) (31)
Comparative Abuse Liability and Pharmacological Effects of Meprobamate, Triazolam, and Butabarbital (2003) (30)
Drugs to decrease alcohol consumption. (1982) (30)
Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. (1999) (30)
The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. (1998) (30)
Binding of diazoxide and other benzothiadiazines to human albumin. (1974) (30)
Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. (1998) (29)
Clinical pharmacology and therapeutics of benzodiazepines. (1978) (29)
Treatment of Codeine Dependence With Inhibitors of Cytochrome P450 2D6 (2002) (29)
Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker (2002) (29)
Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics (2006) (29)
Anxiolytics and sedative/hypnotics dependence. (1991) (29)
A Multiple‐Dose, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray (2013) (29)
Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report. (2009) (29)
Use of Hair Analysis for Confirmation of Self-Reported Cocaine Use in Users with Negative Urine Tests (2001) (28)
Liver granulomas and allopurinol. (1978) (28)
Acute kinetic and dynamic interactions of zimelidine with ethanol (1984) (28)
Mitigating the risk of opioid abuse through a balanced undergraduate pain medicine curriculum (2013) (28)
Further studies on plasma proteins, lipids, and dye- and drug-binding in a child with analbuminemia. (1981) (27)
Effects of 5-HT3 receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal (2005) (27)
Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. (2011) (27)
Low doses of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH DPAT) increase ethanol intake (1994) (27)
Evidence for the contribution of CCKB receptor mechanisms to individual differences in amphetamine-induced locomotion (1994) (27)
Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. (1999) (26)
Human abuse liability evaluation of CNS stimulant drugs (2014) (26)
Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect (2014) (26)
PROPRANOLOL-DECREASED NORADRENALINE EXCRETION AND ALCOHOL WITHDRAWAL (1976) (26)
Long-term benzodiazepine therapy does not result in brain abnormalities. (2000) (26)
Intravascular factors affecting diazepam binding to human serum albumin. (1979) (26)
Characteristics of Long‐term Alprazolam Users in the Community (1992) (26)
Preventing and managing aberrant drug-related behavior in primary care: systematic review of outcomes evidence. (2014) (26)
Dependence liability of two antidiarrheals, nufenoxole and loperamide (1980) (26)
SALIVA AND PLASMA CONCENTRATIONS OF DIAZEPAM AFTER A SINGLE ORAL DOSE (1977) (25)
Corrigendum to “Nicotine metabolism and CYP2A6 activity in a population of black African descent: Impact of gender and light smoking” [Drug Alcohol Depend. 89/1 (2007) 24–33] (2009) (25)
Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro. (1993) (25)
3alpha-reduced neuroactive steroids and their precursors during pregnancy and the postpartum period. (2005) (24)
High-performance liquid chromatographic determination of plasma propylthiouracil. (1979) (24)
Ethanol-induced spontaneous norepinephrine release from the rat vas deferens. (1979) (24)
Oral ketamine as a positive control in human abuse potential studies. (2010) (24)
Ethanol and sympathetic denervation effects on rat adrenal catecholamine turnover. (1980) (23)
Psychedelic Drugs as Therapeutics: No Illusions About the Challenges (2018) (23)
Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist (2016) (23)
Effect of metabolic blockade on the psychoactive effects of dextromethorphan (2010) (23)
Serotonin and alcohol drinking. (1992) (23)
Lithium treatment during alcoholic withdrawal (1976) (22)
Dissociation of serotonergic regulation of anxiety and ethanol self-administration: a study with mCPP. (1994) (22)
Relative abuse potential of opioid formulations in Canada: a structured field study. (2006) (22)
Drug metabolism in the elderly: confounding of age, smoking, and ethanol effects. (1983) (22)
Survival after massive procainamide ingestion. (1973) (21)
Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study (2016) (21)
Propranolol‐Associated Confused States during Alcohol Withdrawal (1983) (21)
Studies with psychedelic drugs in human volunteers (2017) (21)
Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. (2010) (20)
A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam. (2000) (20)
Management of the alcohol withdrawal syndrome. (1991) (20)
Diazepam actions and plasma concentrations following ethanol ingestion (2004) (20)
Variations in drug free fraction during alcohol withdrawal. (1983) (19)
Catalytic and immunologic similarities between monkey and human liver cytochrome P-450db1 (human cytochrome P-450 2D6). (1992) (19)
Enhancement of warfarin‐induced hypoprothrombinemia by triclofos (1972) (19)
Preliminary findings with the indirect 5-HT agonist dexfenfluramine on heroin discrimination and self-administration in rats (1993) (19)
Inhibition kinetics of cationic drugs on N'-methylnicotinamide uptake by brush border membrane vesicles from the dog kidney cortex. (1990) (19)
The Effect of Multiple Doses of Peginterferon alfa‐2b on the Steady‐State Pharmacokinetics of Methadone in Patients With Chronic Hepatitis C Undergoing Methadone Maintenance Therapy (2007) (19)
Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria. (2012) (19)
Randomized Open-Label Drug-Drug Interaction Trial of Dextromethorphan/Quinidine and Paroxetine in Healthy Volunteers (2012) (19)
Enalapril effects on alcohol intake and other consummatory behaviors in alcoholics (1991) (19)
The Role of Cytochrome P450 2C19 Activity in Flunitrazepam Metabolism In Vivo (2003) (19)
Influence of 5-HT3 receptor antagonists and the indirect 5-HT agonist, dexfenfluramine, on heroin self-administration in rats (1994) (18)
The effect of propranolol on normal physiologic tremor. (1976) (18)
Psychosis with Vicks Formula 44-D abuse. (1992) (18)
Effect of adverse drug reactions on the length of hospitalization. (1978) (18)
Comparative Drug Effects and Abuse Liability of Lorazepam, Buspirone, and Secobarbital in Nondependent Subjects (1992) (18)
CYP2D6 phenotype and genotype in a Canadian Native Indian population. (1997) (18)
Differential effects of benzodiazepine disposition by disulfiram and ethanol. (1980) (18)
Long-term alprazolam use: abuse, dependence or treatment? (1991) (18)
Variability in heparin effect on serum drug binding (1980) (18)
Ethanol interactions with serotonin uptake selective and non‐selective antidepressants: Fluoxetine and amitriptyline (1989) (17)
Blood glucose in intoxicated chronic alcoholics. (1975) (17)
Fatty acids modulation of meal-induced variations in diazepam free fraction. (1980) (17)
Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans (2004) (17)
Addictive drugs: disposition, tolerance, and dependence interrelationships. (1978) (17)
Is there an indication for the use of barbiturate-containing analgesic agents in the treatment of pain? Guidelines for their safe use and withdrawal management. Canadian Pharmacists Association. (2000) (17)
Compliance among heavy alcohol users in clinical drug trials. (1988) (17)
Use of serotonin (5-HT) and opiate-based drugs in the pharmacotherapy of alcohol dependence: an overview of the preclinical data. (1996) (17)
Disposition of Intravenous Propylthiouracil (1981) (17)
Diazepam withdrawal seizures. (1982) (17)
CLINICAL IMPLICATIONS OF DRUG—ALBUMIN INTERACTION (1977) (16)
A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor (2018) (16)
2743 – THE CLINICAL IMPORTANCE OF INTERACTIONS BASED ON DISPLACEMENT OF PROTEIN BOUND DRUGS (1978) (16)
Blockade of morphine place conditioning by the CCKA receptor antagonist devazepide. (1991) (16)
Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes (1997) (16)
Assessment of the Abuse Liability of a Dual Orexin Receptor Antagonist: A Crossover Study of Almorexant and Zolpidem in Recreational Drug Users (2014) (15)
The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuse. (1997) (15)
Interaction between opiate and 5-HT3 receptor antagonists in the regulation of alcohol intake. (1994) (15)
Human Abuse Potential and Cognitive Effects of Taranabant, a Cannabinoid 1 Receptor Inverse Agonist: A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study in Recreational Polydrug Users (2012) (15)
Further studies to examine the nature of dexfenfluramine-induced suppression of heroin self-administration (1995) (15)
Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property (2021) (15)
Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent. (2008) (14)
Absorption of oral and intramuscular chlordiazepoxide (1978) (14)
Psilocybin: Good Trip or Bad Trip (2017) (14)
EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study (2004) (14)
Opposite effects of Ro 15-4513 on acquisition and maintenance of ethanol drinking behavior in male Wistar rats. (1997) (14)
Medication discontinuation in panic disorder. Discussion (1993) (13)
Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study (2019) (13)
Use of Omeprazole as a CYP3A Probe Drug: Effect of Sex and Menstrual Cycle Phase on CYP3A Activity in Healthy Caucasian Adults (2006) (13)
Pharmacokinetic and pharmacodynamic drug interactions: implications for abuse liability testing. (1989) (13)
Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19. (2002) (13)
Influence of cold exposure and thyroid hormones on regulation of adrenal catecholamines. (1977) (13)
Treatment of the barbiturate abstinence syndrome * (1986) (13)
The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential. (2010) (13)
Designer Drugs That Are Potent Inhibitors of CYP2D6 (2002) (13)
An application of computers to curriculum review and planning. (1986) (13)
Effect of CYP2D1 inhibition on the behavioural effects of d-amphetamine. (1997) (13)
Adverse biochemical and clinical consequences of furosemide administration. (1978) (13)
Unaltered diazepam plasma binding using indwelling heparinized cannulae for sampling. (1980) (12)
Chloral hydrate and warfarin therapy. (1971) (12)
Use of benzodiazepines. (1980) (12)
Naltrexone in the treatment of alcohol dependence: a Canadian trial. (2002) (12)
Brain Network Activation (BNA) Reveals Scopolamine-Induced Impairment of Visual Working Memory (2014) (12)
Diazepam and N‐Desmethyldiazepam in Saliva of Hospital Inpatients (1980) (12)
Plasma protein binding of phencyclidine (1982) (12)
Influence of cimetidine and ranitidine on ethanol pharmacokinetics. (1986) (12)
Pharmacological control of alcohol consumption: tactics for the identification and testing of new drugs. (1981) (11)
Effects of quinidine on the renal tubular and biliary transport of digoxin: in vivo and in vitro studies in the dog. (1988) (11)
Effect of naltrexone and its derivatives, nalmefene and naltrindole, on conditioned anticipatory behaviour and saccharin intake in rats (1997) (11)
Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users. (2012) (11)
Severe dependence on oral opiods (1998) (11)
Abuse potential of mirogabalin in recreational polydrug users (2019) (11)
Research advances in new psychopharmacological treatments for alcoholism : proceedings of the symposium "Research advances in New Psychopharmacological Treatments for Alcoholism," Toronto, 4-5 October 1984 (1985) (10)
Benzodiazepines as Drugs of Abuse and Dependence (1986) (10)
Effect of 5-HT3 receptor antagonists on the discriminative stimulus properties of morphine in rats (2005) (10)
Effect of pentylenetetrazole on ethanol intake, ethanol kinetics, and social behavior in male Wistar rats. (1998) (10)
Decline in chlordiazepoxide plasma levels during fixed-dose therapy of alcohol withdrawal. (1978) (10)
Alcohol use by patients admitted to hospital emergency rooms for treatment of drug overdose and misuse. (1980) (10)
Cognitive toxicity of drugs used in the elderly (2001) (10)
The Nature and Etiology of Normal and Alcohol Withdrawal Tremor (1979) (10)
Identifying appropriate subjects for abuse liability studies using prestudy pharmacological testing. (1999) (10)
Risk of drug dependence and abuse posed by barbiturate-containing analgesics. (1999) (10)
Diazepam pharmacokinetics after intravenous administration in alcohol withdrawal. (1983) (9)
Pharmacokinetic interaction of propoxyphene with ethanol. (1985) (9)
Defining the true therapeutics and clinical pharmacology curriculum in a canadian medical school: Implications for change (1988) (9)
Nonfatty acid–modulated variations in drug binding due to heparin (1982) (9)
Clinical pharmacokinetics of chlordiazepoxide. (1978) (9)
Serotonin and Alcohol Consumption (1992) (9)
Phencyclidine ingestion: drug abuse and psychosis. (1981) (9)
Drug deprivation and reinforcement by diazepam in a dependent population (2004) (9)
Evaluation of zopiclone physical dependence liability in normal volunteers. (1982) (9)
Effect of dorsal raphe injections of the GABAA agonist, muscimol, on ethanol intake and measures of intoxication in Wistar rats. (1994) (9)
Alcohol and Drug Dependence (2019) (9)
Disposition of intravenous diazepam in young men and women (2004) (8)
Deconstructing Designer Drugs (2017) (8)
Clinical detection and assessment of drug induced neurotoxicity. (1981) (8)
Perception of Whether Drug or Placebo Has Been Administered Is a Determinant of Drinking Reduction (1992) (8)
Effects of low-dose opioids on cognitive dysfunction. (2011) (8)
Inhibition of nicotine's metabolism: A potential new treatment for tobacco dependence (1999) (8)
Effect of oral contraceptives (OCS) on drug metabolizing enzymes (DMES) as measured by the validated cooperstown 5+1 cocktail (5+1) (2003) (8)
Lack of Weight‐Based Dose Dependency and Intraindividual Variability of Omeprazole for CYP2C19 Phenotyping (2004) (8)
Effects of Angiotensin Converting Enzyme Inhibitors on Free Choice Ethanol Consumption by Rats (1992) (8)
Drug metabolism and interactions in abuse liability assessment. (1991) (7)
Comparative Neurologic Effects of Diazepam and Suriclone, a Cyclopyrrolone Anxiolytic (1988) (7)
Conference on drug formulations and abuse liability (2006) (7)
Probable interaction of loperamide and cholestyramine. (1978) (7)
The documented role of pharmacogenetic: in the identification and administration of new medications for treating drug abuse. (1996) (7)
Adverse drug reactions: uncommon or unrecognized? (1979) (7)
Nonpharmacological Supportive Care Compared to Chlormethiazole Infusion in the Management of Severe Acute Alcohol Withdrawal (1982) (7)
Unaltered serum propranolol binding by meal-induced variations in fatty acids. (1982) (7)
Age- and sex-related differences in patterns of drug overdose and abuse. (1981) (7)
Neurosteroids: A New Regulatory Function in the Nervous System (1999) (6)
Mechanism of alterations in propylthiouracii disposition after long‐term therapy (1982) (6)
Inhibition of CYP2A6 decreases smoking (1999) (6)
Alcohol intoxication and the alcohol withdrawal syndrome. (1978) (6)
Serotonin Uptake Inhibitors Attenuate Ethanol Intake in Humans (1988) (6)
Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users (2018) (6)
A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers. (2012) (6)
Use of serotonin (5-HT) and opiate-based drugs in the pharmacotherapy of alcohol dependence: an overview of the preclinical data. (1996) (6)
A Study of Potential Pharmacokinetic and Pharmacodynamic Interactions between Dextromethorphan/Quinidine and Memantine in Healthy Volunteers (2012) (6)
Phase Ib clinical trial of aerosolized liposome encapsulated fentanyl (AeroLEF™) (2004) (6)
The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond (2014) (6)
Pharmacotherapy of Alcohol Dependence: Improving Translation from the Bench to the Clinic (2008) (6)
Relevance of deficient CYP2D6 in opiate dependence (1998) (5)
Randomized, Double-Blind, Placebo- and Active Comparator–Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users (2017) (5)
THE INFLUENCES OF GROUP AND INDEPENDENT GENERAL PRACTICE ON PATIENT CARE: A COMPARATIVE STUDY IN ONTARIO. (1965) (5)
Analysis of Plasma Diethyldithiocarbamate–A Metabolite of Disulfiram (1982) (5)
Interaction of serotonin uptake inhibitors with ethanol (1988) (5)
Antihypertensive efficacy of propranolol given twice daily. (1979) (5)
5-HT Mediation of Alcohol Self-Administration, Tolerance and Dependence: Pre-Clinical Studies (1995) (5)
Effect of alcohol on propylthiouracil disposition (1983) (5)
Determination of free propylthiouracil clearance and single sample prediction of steady state (1982) (5)
Assessing the abuse potential of an oral osmotic-controlled extended release (OROS) hydromorphone compared to immediate release hydromorphone (2009) (5)
Oral anticoagulant therapy. (1972) (5)
Effect of dexfenfluramine on saccharin drinking: Behavioural and pharmacological studies (1994) (5)
Use of drugs with dependence liability. (1979) (5)
Letter: Propranolol-decreased noradrenaline excretion and alcohol withdrawal. (1976) (5)
Effect of Cytochrome P 450 2 D 1 Inhibition on Hydrocodone Metabolism and its Behavioral Consequences in Rats 1 (1997) (5)
Psychoactive drug use in the elderly: the pharmacokinetics. (1979) (5)
Lack of correlation between CYP3A probes and midazolam in healthy caucasian women on or off oral contraceptives (OCS) (2003) (4)
Pharmacotherapy of alcohol and drug problems. (1991) (4)
New strategies for the treatment of alcohol withdrawal. (1986) (4)
Letter: Effect of propranolol on tremor of alcohol withdrawal. (1976) (4)
Opioids: The Painful Public Health Reality (2018) (4)
P.6.c.010 Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users (2010) (4)
Limitations in the measurement of urine ethanol in clinical trials to monitor ethanol consumption. (1988) (4)
The Interaction of the Serotoninergic and Other Neuroregulatory Systems in Alcohol Dependence (2000) (3)
An improved HPLC method for analysis of methamphetamine and its metabolites in plasma (1997) (3)
Defining rational prescribing of psychoactive drugs. (1988) (3)
Therapeutic use of serotonergic drugs in alcohol abuse. (1986) (3)
Variations in serum dopamine beta-hydroxylase in normal subjects and chronic alcoholics. (1978) (3)
Amitriptyline Blood Levels and Relapse (1977) (3)
New Method for Fluoride Determination (1957) (3)
Abstracts of Presentations at the International Conference on Basic and Clinical Multimodal Imaging (BaCI), a Joint Conference of the International Society for Neuroimaging in Psychiatry (ISNIP), the International Society for Functional Source Imaging (ISFSI), the International Society for Bioelectr (2013) (3)
Enalapril Does not Decrease Alcohol Intake in Normotensive Alcoholics (1992) (3)
Diazepam withdrawal syndrome. (1983) (3)
Oral intact extended-release oxymorphone is associated with less liking and lower positive subjective effects than equianalgesic doses of oral intact controlled-release oxycodone in healthy nondependent recreational opioid users (2010) (3)
Impurities in Street Phencyclidine (1975) (3)
Efficacy of dexfenfluramine in the treatment of alcohol dependence. (2000) (3)
Drug‐plasma protein binding in Kutchin Athapaskan Indians (1982) (3)
Use of the overturn end point in goldfish to measure the interaction of diazepam and ethanol and the effects of the binding of diazepam to bovine serum albumin. (1979) (2)
FACULTY PERCEPTIONS OF A MEDICAL SCHOOL LEARNING ENVIRONMENT (1987) (2)
(235) Evaluation of abuse potential of ALO-01, an extended-release morphine sulfate plus sequestered naltrexone formulation, among recreational opioid users (2008) (2)
Failure of acetylmethadol in treatment of narcotic addicts due to nonpharmacologic factors. (1976) (2)
Parenteral 5-Fluorocytosine for Candidiasis (1979) (2)
(754): The effect of ethanol co-administration with morphine on pharmacodynamic (PD), pharmacokinetic (PK) and safety measures in healthy volunteers (2007) (2)
Will Heroin Improve Pain Management? (1985) (2)
Categorization of Abuse Potential–Related Adverse Events (2018) (2)
Medications for Alcohol Abuse and Dependence: Methodology for Clinical Studies (1992) (2)
Kinetic and dynamic interactions of oral viqualine and ethanol in man (2004) (2)
Letter: Propranolol effect on tremor in alcoholic withdrawal. (1975) (2)
Mania and cough syrup. (1993) (2)
Lack of effect of cimetidine on cigarette smoking (2004) (2)
Binding of drugs to ion-exchange resins in simulated gastric fluid. (1978) (2)
Deans' attitudes toward teaching psychopharmacology and rational prescribing in medical schools. (1987) (2)
Patterns of benzodiazepine (B) use and dependence in Canada (1999) (2)
Pharmacodynamic and Pharmacokinetic Drug Interactions with Coumarin Anticoagulants (2012) (2)
Recreational drug user preferences: Egalet® opioids have low abuse and tampering attractiveness relative to marketed opioids (2009) (2)
Partial Agonist Properties and Toxicity of Oral Oxilorphan (1976) (2)
Improving reliability and validity of adverse drug reaction assessment in psychopharmacology (1983) (2)
5-HT2A and 5-HT2C receptors as potential targets for the treatment of nicotine use and dependence. (2021) (2)
Institutional Strategies, A Key to Successful Curriculum Change (1988) (2)
Ethanol-induced inhibition of hepatic uptake of propranolol in perfused rat liver and in man (2004) (2)
Detoxification for triazolam physical dependence. (1992) (2)
Assessment of human abuse potential of preladenant (a centrally-acting A2A antagonist) compared to phentermine and placebo in recreational stimulant users (2015) (1)
A randomized, double-blind, placebo-controlled, crossover study to evaluate the abuse potential of purified cannabidiol (CBD) in subjects with a history of recreational polydrug use (P1.266) (2018) (1)
Severe Dependence on Oral Opiates (1996) (1)
A Message from the President—Come to Walt Disney World, Orlando, March 17–20, 1982 (1982) (1)
Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 2 Optimizing the Design of Human Abuse Potential Studies (2018) (1)
Does Extent of p‐Hydroxylation Alter Methamphetamine Kinetics (1996) (1)
in a population of Black African descent (2010) (1)
Systematic review: managing aberrant drug behavior in primary care (2013) (1)
Mechanisms of ethanol drug interactions (1982) (1)
Identification of Optimal Measures of Human Abuse Potential (2020) (1)
ABUSE LIABILITY OF BRETAZENIL AND OTHER PARTIAL AGONISTS (1992) (1)
Characterization of Dsm-IIIr Criteria for Uncomplicated Alcohol Withdrawal: Proposal for a Diagnostic Inventory and Revised Withdrawal Scale (1992) (1)
Spurious detection of a high serum imipramine level due to coating of Vacutainer stopper. (1982) (1)
Letter: Alcohol and organic disease: calculation of consumption. (1976) (1)
Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 1 Regulatory Context and Risk Management (2017) (1)
Summary of the Guidelines for the Use of Psychotropic Drugs in the Treatment of Anxiety (1984) (1)
Clinical pharmacology in Canada (1974) (1)
Oral ketamine as a positive control in abuse liability studies (2004) (1)
Human plasma binding of warfarin. Displacement effect of several antimicrobials. (1978) (1)
THE PHARMACOKINETIC COMPONET OF DRUG EFFECTS ON DRIVING SKILLS (1974) (1)
DEVELOPING AN ANIMAL MODEL OF DRUG CRAVING (1996) (1)
Mechanism of alterations in propylthiouracil disposition after long-term therapy. (1982) (1)
Protein-binding of drugs. (1970) (1)
Adverse Drug Reaction Probability Scale (2016) (1)
FLUNITRAZEPAM METABOLISM BY CYTOCHROME P 450 S 2 C 19 AND 3 A 4 (2001) (1)
An Interview Study of Hospitalized Drug Overdose Patients (1978) (1)
S-31-1 Metabolism, kinetics and interactions in treating refractory depression (1996) (1)
Discussion on How and When Can This Approach Be Applied and Initial Reactions (1986) (1)
Applying brain network activation tool on working memory ERPs in a scopolamine model of Alzheimer's disease (2011) (0)
Medications to treat alcoholism? (1993) (0)
Therapeutic use of heroin: the scientist's role in social policy development. (1986) (0)
Ethanol-psychotropic drug interactions: pharmacokinetics. (1984) (0)
Novel therapeutic agents: A multi-centre open-label, dose-escalation study of intramuscular tetrodotoxin for severe cancer pain (2004) (0)
Clinical pharmacology andtherapeutics ofbenzodiazepines (1978) (0)
Evaluation of human abuse liability of JZP-110 (2017) (0)
Inhibition ofhumancytochrome P4502D6(CYP2D6) by methadone (1993) (0)
Substance dependence in elderly people. (2001) (0)
Serotonin neurochemistry and psychopharmacology in 1986 (1987) (0)
Putting computers to work for curriculum planners. (1985) (0)
Pharmacology teaching at the University of Toronto: A survey of students and graduates (1979) (0)
Recent Developments in Alcoholism, Vol. 4, Combined Alcohol and Drug Abuse Problems, Typologies of Alcoholics, the Alcohol Withdrawal Syndrome, and Renal and Electrolyte Consequences of Alcohol Abuse (1987) (0)
P.5.e.006 Scopolamine: modelling memory and cognitive deficits for clinical trials (2008) (0)
Enalapril does not alter consummatory behaviors in problem drinkers (1990) (0)
Treatment of the Acute Alcohol Withdrawal State: A Comparison of Four Drugs (1995) (0)
Effects of the 5-HT Uptake Inhibitor, Sertraline, on Ethanol, Water and Food Consumption (1992) (0)
Oral intact extended-release oxymorphone is associated with less cognitive and psychomotor impairment than equianalgesic doses of oral intact controlled-release oxycodone in healthy nondependent recreational opioid users (2010) (0)
Psychedelics: Science sabotaged by Social Media (2023) (0)
P.6.e.003 Alprazolam-induced changes in cognitive and psychomotor performance in subjects with a history of recreational sedative-hypnotic drug use (2006) (0)
OF 18-METHOXYCORONARIDINE , AN IBOGAINE ANALOG , TO 18-HYDROXYCORONARIDINE BY GENETICALLY VARIABLE CYP 2 C 19 (2002) (0)
following tamoxifen use (2007) (0)
2842 – FLUCTUATIONS OF PLASMA DIAZEPAM (D) AND N-DESMETHYLDIAZEPAM (DM) CONCENTRATIONS (1978) (0)
Long-acting cocaine esterase (LACE): Assessing the treatment approach (2014) (0)
P.6.c.009 Eplivanserin has no significant abuse potential compared to diazepam and ketamine in recreational drug users (2010) (0)
P.6.d.009 Abuse deterrent opiate formulations: an imperfect solution to a perfect storm? (2014) (0)
P.6.f.005 Explicit claims for tamper resistant and abuse deterrent opiates: FDA draft guidance (2013) (0)
Modifying the Metabolism of Nicotine as a Therapeutic Strategy (2008) (0)
Antianxiety drugs in alcohol withdrawal. (1978) (0)
Corrigendum: The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting (2017) (0)
A Reply to Dr Andrew Johns (1988) (0)
a World Health Organization Collaborating Center News and Views (1995) (0)
570 – ADRENERGIC COMPONENT OF ALCOHOLIC WITHDRAWAL (1977) (0)
Clinical pharmacology of anticoagulants. (1977) (0)
P.1.g.014 Cognitive and neurophysiological performance following scopolamine and ketamine administration in a crossover study (2010) (0)
P.6.c.009 Human abuse potential studies: subjective response patterns and clinically relevant effects of abused drugs (2008) (0)
Scopolamine: Modeling cognitive deficits associated with Alzheimer's disease via novel functional brain imaging and network analysis (2010) (0)
P.1.c.008 Various ethanol doses combined with morphine 30 mg do not affect pharmacodyanmic and pharmacokinetic measures (2007) (0)
2330 – INTERINDIVIDUAL VARIATIONS IN PLASMA PROTEIN BINDING OF DIAZEPAM (D) (1978) (0)
Abuse potential of a dual orexin receptor antagonist: A randomized, double-blind, crossover study in recreational drug users (2015) (0)
P.6.c.0101 Pharmacodynamic response patterns to ketamine, zolpidem, and diazepam in abuse liability studies (2009) (0)
Psychiatric Comorbidity and Dependence in Regular Users of Codeine (1996) (0)
SEROTONERGIC COMPOUNDS IN THE TREATMENT OF ALCOHOLISM (1992) (0)
Dr. Sellers replies (1988) (0)
The Brain as a Drug Metabolizing Organ: Genetic Variability in CNS Opiate Metabolism. (1995) (0)
Inhibitor combinations CYP2A enzyme and nicotine and its therapeutic utilizon. (1998) (0)
Teaching medical students about alcoholism. (1984) (0)
Evaluation of abuse potential of brivaracetam in healthy recreational CNS depressant users (P6.243) (2017) (0)
COMPARISONOFTWO RECENTLYPUBLISHEDALGORITHMS FORASSESSINGTHE PROBABILITYOFADVERSE DRUG REACTIONS (1982) (0)
Ecopipam (SCH 39166), A D1 antagonist, on acute effects of cocaine (1999) (0)
Gusto : a journey through culinary design (2010) (0)
706 Ethnic variation in CYP2A6: impact on smoking and health consequences (2000) (0)
Clinical Institute Withdrawal Assessment for Alcohol (CIWA) 1989 (1989) (0)
Brain Network Activation (BNA) Reveals Scopolamine-Induced Impairment of Visual Working Memory (2014) (0)
The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond (2014) (0)
Adverse biochemical and clinical consequences of furosemide administration. (1978) (0)
Clinical Textbook of Addictive Disorders (1992) (0)
Socioeconomic and drug use determinants of smoking status in a Canadian urban adult population of black African descent (2018) (0)
Clinical competence and curiosity (1986) (0)
College on problems of drug dependence presidential address 1995. Evidence-based treatment and prevention: research for the health of the public. (1996) (0)
Biobehavioural basis of pharmacologic treatment of alcohol dependence. (1994) (0)
Claudio A. Naranjo, MD (1945-2014). (2015) (0)
PII‐73 (2006) (0)
Drug use as a lifestyle in the 1980s. (1983) (0)
Early pragmatists. (1966) (0)
Method and apparatus for tissue-kräuselbestimmung (1991) (0)
Subject Index, Vol. 27 (Suppl 2), 1983 (1983) (0)
Pharmacokinetic interaction ofpropoxyphene withethanol (1985) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Edward M. Sellers?

Edward M. Sellers is affiliated with the following schools:

Edward M. Sellers's Academic­Influence.com Rankings

Edward M. Sellers's Degrees

Similar Degrees You Can Earn

Why Is Edward M. Sellers Influential?

Edward M. Sellers's Published Works

Published Works

What Schools Are Affiliated With Edward M. Sellers?

Edward M. Sellers's AcademicInfluence.com Rankings